Lv6
2879 积分 2022-03-04 加入
Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding
2天前
已完结
Structural basis of sex pheromone detection in aphids
17天前
已完结
How Does a Drug Molecule Find Its Target Binding Site?
18天前
已完结
How Does a Drug Molecule Find Its Target Binding Site?
18天前
已完结
How Fast-Folding Proteins Fold
23天前
已完结
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
2个月前
已完结
How should the efficacy of novel treatments be assessed in survival trials?
7个月前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
7个月前
已完结
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
11个月前
已完结
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
11个月前
已完结
皖公网安备34019202002308
